OR-FLIR-SYSTEMS-INC
22.1.2019 17:01:13 CET | Business Wire | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) today announced the Raymarine DockSense™ assisted docking system, the marine industry’s first intelligent object recognition and motion sensing assisted docking solution for recreational boating. DockSense system uses FLIR machine vision camera technology and video analytics to integrate intelligence gathered from surrounding imagery with the vessel’s propulsion and steering system to assist boat owners in tight quarter docking maneuvering. Additionally, FLIR announced that Prestige Yachts, a Groupe Beneteau brand, will become the first to demonstrate the technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190122005313/en/
Docking a boat can be a stressful experience, even for the most experienced captains. Often wind and tides make the task more difficult, and docking mishaps can become expensive repairs and safety hazards. The DockSense system is designed to augment a captain's boat handling skills using the system’s Virtual Bumper™ zone technology around the vessel. Should an object like a piling or another vessel encounter the Virtual Bumper, DockSense automatically introduces corrective steering and throttle commands to avoid the object and assist the captain in guiding the vessel to the dock.
DockSense uses global positioning system (GPS) and attitude heading reference system (AHRS) position sensing technology to compensate for the effects of wind and currents, ensuring the vessel enters the dock without drama or costly collisions. The Raymarine DockSense system includes multiple FLIR machine vision cameras, a central processing module, and the DockSense App running on Raymarine’s Axiom navigation display. The system integrates with modern joystick propulsion systems, providing assisted steering and throttle commands to help captains make a smooth arrival.
“Raymarine DockSense assisted docking system embodies our focus on solutions by combining FLIR navigation, machine learning, and sensing technologies,” said Jim Cannon, President, and CEO of FLIR. “Most importantly, we bring these innovations together into a simple solution that addresses a key customer challenge by taking the stress out of docking a boat and makes the boating experience safer and more enjoyable for everyone onboard.”
“Our goal is to be the global benchmark for all boating experiences,” said Hervé Gastinel, CEO of Groupe Beneteau. “The Raymarine DockSense solution will give future Prestige owners the confidence to dock safely and aligns with our vision to simplify the boating experience and make boating accessible to a much larger audience”, confirms Erik Stromberg, Prestige product marketing director.
FLIR will preview Raymarine DockSense technology at the Dusseldorf Boat Show in, Germany from January 19 – 27 at the Raymarine stand (Hall 11, Stand A42 ) and the Prestige stand (Hall 6, Stand D57). DockSense will also be demonstrated on a Prestige 460 motor yacht during the Miami Boat Show in February 2019.
To learn more, visit http://www.raymarine.com/docksense .
About FLIR Systems
Founded in 1978 and headquartered in Wilsonville, Oregon, FLIR Systems is a world-leading maker of sensor systems that enhance perception and heighten awareness, helping to save lives, improve productivity, and protect the environment. Through its nearly 3,500 employees, FLIR's vision is to be "The World's Sixth Sense" by leveraging thermal imaging and adjacent technologies to provide innovative, intelligent solutions for security and surveillance, environmental and condition monitoring, outdoor recreation, machine vision, navigation, and advanced threat detection. For more information, please visit http://www.flir.com and follow @flir .
About Prestige
A major international brand, PRESTIGE has positioned itself in the highly exacting market of luxury motor yachts. Manufactured in Vendée – France and devised by yachtsmen for those who love the sea, PRESTIGE® yachts are the jewel of French marine engineering. With the Garroni Studio, PRESTIGE designs the most livable yachts from 40 to 75 feet. Both FLYBRIDGE and SPORT ranges offer contemporary, high-design and clever motor yachts. The brand relies on an ever-growing worldwide professional dealer network. For more information please visit http://www.prestige-yachts.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005313/en/
Contact:
FLIR Media Contact Tim McDowd 503-498-3146 tim.mcdowd@flir.com
FLIR Investor Relations Jay Gentzkow 503-498-3809 Jay.gentzkow@flir.com
Prestige Press contact Elise Vinet +33670643397 e.vinet@jeanneau.fr
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom